Seeking Alpha

Sometimes hindsight may not always be such a wonderful thing, especially for Human Genome...

Sometimes hindsight may not always be such a wonderful thing, especially for Human Genome Sciences (HGSI). The drug developer, which agreed to be bought by GlaxoSmithKline (GSK) earlier this month for $14.25 per share, says it received and rejected a much higher $35 per share takeover bid by Amgen (AMGN) back in August, 2010. It decided not to sell at the time because regulatory approval for its lupus drug Benlystsa was expected later that year. Ah, if only...
Comments (1)
  • BIGGS48
    , contributor
    Comments (13) | Send Message
     
    This sale is a travesty for shareholders. Most (shareholders) stayed in the stock primarily because a drug to treat lupus, the first in 50 years, was shown to be the most effective for the disease...ever. Help mankind and make money was a feel good story for an investor. Now these clowns sell us short. They were so self righteous; putting out the clarion call for investors to actively reject Glaxo's offer at $13.00 per share. So, an additional $1.25 is a good deal? Please!
    26 Jul 2012, 10:44 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector